Omeros Corporation (OMER:NASDAQ) closed at $16.20 on October 16, 2026, down 13.78% on the day. The stock trades 23.7% below its 52-week high of $21.24 and 159.6% above its 52-week low of $6.24. Over the past year, it gained 91.1%. Omeros Corporation is part of the Health Care sector (Major Pharmaceuticals).
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -4.28% | +8.36% | +95.12% | +39.50% | +91.15% |
In 252 trading sessions since October 15, 2025, OMER closed higher on 127 days (50%). Its best day was October 15, 2025 (+154.15%) and its worst was June 26, 2026 (-19.12%). The stock moved 10% or more in a single session 17 times. It opened at least 5% above the previous day's high 6 times.
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use during cataract surgery or intraocular lens replacement. Its clinical programs include OMS721 that is in Phase III clinical trial for the treatment of atypical hemolytic uremic syndrome; and in Phase II clinical trial to treat thrombotic microangiopathies, IgA nephropathy, and other renal diseases. The company's clinical programs also consists of OMS824, which is in Phase II clinical trial for the treatment of Huntington's diseases and schizophrenia; OMS405 that is in Phase II clinical trial to treat opioid and nicotine addiction; and OMS201, which is in Phase I/II clinical trial for use during urological procedures. Its preclinical programs comprise OMS527 for the treatment of addiction and compulsive disorders, as well as for movement disorders; OMS906 to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; OMS721 for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular d...
Find more stocks like OMER with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.